Small intestinal bacterial overgrowth (SIBO): how is it diagnosed, how reliable is breath testing, and does rifaximin work?

What it is

The American College of Gastroenterology defines SIBO as excessive numbers of bacteria in the small bowel that cause gastrointestinal symptoms. It is diagnosed either by culturing fluid drawn from the duodenum or jejunum, or, more commonly, by breath tests that measure hydrogen (and methane) after a drink of glucose or lactulose.

What the research says

The evidence here is limited. Breath tests, the usual way SIBO is diagnosed, missed roughly half of cases when checked against jejunal culture in a 2020 meta-analysis, and culture itself is an imperfect reference. The antibiotic rifaximin cleared a positive test in about 59% to 71% of patients in pooled analyses, but the guideline that recommends antibiotics rates its own evidence as low. People with IBS test positive more often than healthy controls, but that is an association, not proof that SIBO causes IBS.

Evidence grade: Limited evidence.

What goes wrong

A meta-analysis of rifaximin cited by the ACG guideline reported adverse reactions in 4.6% of patients, and the guideline warns of resistance and Clostridioides difficile with wider antibiotic use. (Source 1)

• Meta-analysis, Low certainty.
• Size: Not stated in the excerpt.
• Who: Patients with SIBO treated with rifaximin.
• How long: Varied by study.
• Result: Adverse reactions 4.6%.
• Funding: Not stated.

rise of opportunistic infections such as Clostridioides difficile, a more cautious approach is needed

What the evidence supports

In pooled observational studies, people with IBS were more likely than healthy controls to test positive for SIBO. (Source 2)

• Meta-analysis, Low certainty.
• Size: 25 studies.
• Who: Adults with IBS and healthy controls (cohort, case-control and cross-sectional studies)
• How long: Not applicable (prevalence comparison)
• Result: OR 5.71 (95% CI 3.45 to 9.45)
• Funding: Independent (no financial support declared)

The pooled risk of SIBO was significantly higher in IBS patients compared to healthy controls

Rifaximin cleared a positive SIBO test in about 59% of IBS patients with SIBO in a pooled analysis of observational studies, with no placebo comparison in the pooled rate. (Source 2)

• Meta-analysis, Low certainty.
• Size: Subset of 25 observational studies.
• Who: IBS patients with concomitant SIBO.
• How long: Varied by study.
• Result: Pooled eradication rate 59% (95% CI 0.48 to 0.68); doses of 1,200 mg/day or more slightly better.
• Funding: Independent (no financial support declared)

Rifaximin treatment achieved a pooled SIBO eradication rate of 59%

A meta-analysis of 32 rifaximin studies (mostly cohort studies, only 7 randomised trials), cited by the 2020 ACG guideline rather than run by the ACG, reported rifaximin succeeded in about 71% of patients by intention to treat. (Source 1)

• Meta-analysis, Low certainty.
• Size: Not stated in the excerpt.
• Who: Patients with SIBO.
• How long: Varied by study.
• Result: Overall success 70.8% (CI 61.4 to 78.2) by intention to treat.
• Funding: Not stated.

the overall success of therapy with an intention-to-treat was 70.8% (CI = 61.4–78.2)

The ACG (2020) suggests antibiotics for symptomatic SIBO but grades this conditional with low-level evidence. (Source 1)

• Official position, Low certainty.
• Size: Not applicable.
• Who: Guideline statement.
• How long: Not applicable.
• Result: Not applicable.
• Funding: Not stated.

We suggest the use of antibiotics in symptomatic patients with SIBO to eradicate overgrowth and resolve symptoms (conditional recommendation, low level of evidence).

What the evidence does not support

Checked against jejunal aspirate culture, lactulose and glucose breath tests missed a large share of cases. (Source 3)

• Meta-analysis, Low certainty.
• Size: 14 diagnostic accuracy studies.
• Who: People tested for SIBO with breath test and jejunal culture.
• How long: Not applicable.
• Result: Pooled sensitivity: lactulose 42.0%, glucose 54.5%; pooled specificity: lactulose 70.6%, glucose 83.2%.
• Funding: Independent (financial support: none)

Pooled sensitivity of LBT and GBT was 42.0% and 54.5%, respectively.

The review authors cite an earlier study (Sundin et al) showing that culture, the reference test, may underestimate bacterial load and agrees poorly with breath tests; this is not a result of the review itself. (Source 3)

• Systematic review, Low certainty.
• Size: 14 studies.
• Who: People tested for SIBO.
• How long: Not applicable.
• Result: Qualitative limitation stated by the authors.
• Funding: Independent (financial support: none)

Sundin et al showed that cultures may frequently underestimate the real bacterial load and that the correlation between microbiological results and BT results is weak.

The ACG guideline itself states that current breath tests have low sensitivity and specificity. (Source 1)

• Official position, Very low certainty.
• Size: Not applicable.
• Who: Guideline statement.
• How long: Not applicable.
• Result: Not applicable.
• Funding: Not stated.

It is recognized that the current breath tests have low sensitivity and specificity and that additional validation studies are needed for standardization.

In a large retrospective US cohort, rifaximin for SIBO was not associated with a statistically significant increase in C. difficile infection within 60 days. (Source 4)

• Cohort study, Low certainty.
• Size: 19,597 matched patients per group.
• Who: Adults with SIBO, treated with rifaximin vs untreated.
• How long: 60 days.
• Result: CDI 0.21% vs 0.15% (p = 0.152)
• Funding: Independent (no external funding)

CDI occurred in 0.21% of Rifaximin-treated patients and 0.15% of untreated patients (p = 0.152).

Where the evidence is mixed

Breath tests performed better in people who had had gastrointestinal surgery than in people with no predisposing condition. (Source 3)

• Meta-analysis, Low certainty.
• Size: Surgical subgroup of 3 studies.
• Who: People with and without abdominal surgery history.
• How long: Not applicable.
• Result: Glucose breath test sensitivity 81.7% and specificity 78.8% after surgery vs sensitivity 40.6% and specificity 84.0% without a predisposing condition.
• Funding: Independent (financial support: none)

BTs demonstrate the best effectiveness in patients with surgical reconstructions of gastrointestinal tract.

In a retrospective study cited by the ACG guideline, proton pump inhibitor use was more common among people with a positive duodenal culture; this is an association only. (Source 1)

• Cohort study, Very low certainty.
• Size: 1,263 duodenal aspirates.
• Who: Patients undergoing duodenal aspirate culture.
• How long: Not applicable.
• Result: PPI use 52.6% in culture-positive vs 30.2% in culture-negative.
• Funding: Not stated.

PPI use was significantly more prevalent in patients with positive duodenal culture results compared with those with negative cultures (52.6% vs 30.2%)

Where the research disagrees

Whether breath testing is good enough to diagnose SIBO

• American College of Gastroenterology (2020), Guideline (position): We suggest the use of breath testing (glucose hydrogen or lactulose hydrogen) for the diagnosis of SIBO in patients with IBS (conditional recommendation, very low level of evidence). (Source 1)
• Losurdo et al. (2020) meta-analysis, Diagnostic accuracy meta-analysis of 14 studies: Pooled sensitivity of LBT and GBT was 42.0% and 54.5%, respectively. (Source 3)

How much

• Studied: Rifaximin at 1,200 mg/day or more was compared with lower doses in pooled observational data (a prescription antibiotic, not a supplement). (Source 2)

A common belief, and what the research shows

The belief: A positive home or clinic breath test proves you have SIBO.

What the research shows: Against culture, breath tests had pooled sensitivity of only 42.0% (lactulose) and 54.5% (glucose), and the ACG says: "It is recognized that the current breath tests have low sensitivity and specificity and that additional validation studies are needed for standardization."

Questions and answers

How is SIBO diagnosed?

Guidelines accept either a culture of fluid from the duodenum or jejunum, or a glucose or lactulose breath test in which hydrogen rises by at least 20 ppm within 90 minutes. Breath tests are used most because culture is invasive. (Source 1)

How reliable is breath testing for SIBO?

Not very. Against jejunal culture, lactulose tests detected 42% and glucose tests 55% of cases, with specificity of 71% and 83%. Accuracy was better after gut surgery, and the culture reference itself is imperfect. (Source 3)

Does rifaximin work for SIBO?

Pooled data show rifaximin clears a positive test in roughly 59% to 71% of patients, but most studies were not placebo-controlled, and the ACG rates the evidence for antibiotics as low. A large cohort did not find a significant rise in C. difficile risk. (Source 2)

What is it?

SIBO means an excess of bacteria in the small intestine that causes digestive symptoms. It is a clinical diagnosis based on symptoms plus a test, not a single organism. (Source 1)

What does it do in the body?

It is linked to digestive symptoms and is found more often in people with IBS than in healthy people. The studies are observational, so they do not show that SIBO causes IBS. (Source 2)

Is it good or bad for you?

By definition SIBO is a symptomatic condition, so it is considered a problem when present. The difficulty is that the tests used to diagnose it are unreliable, so many labels may be wrong. (Source 1)

How do you get more of it?

Does not apply: SIBO is a condition, not something people seek more of. (Source 1)

We searched: Not searched; question does not apply to a condition.

If it is harmful, what reduces it?

Antibiotics, mainly rifaximin, are the studied treatment; pooled success rates are about 59% to 71%, with low-certainty evidence. Diet and probiotic approaches were not assessed in the sources reached this session. (Source 1)

Why might someone be low in it or missing it (or, here, why might it develop)?

Risk factors in the sources include previous gut surgery (where breath tests work best) and acid-suppressing proton pump inhibitors, which were more common in people with positive cultures in a retrospective study. (Source 1)

Which whole foods contain it or feed it?

No food-based evidence for causing or treating SIBO was found in the sources reached this session. (Source 1)

We searched: Searched rifaximin and breath-test reviews; diet trials for SIBO were not reached.

What happens if you do not have it?

Not having SIBO is the normal state. The practical problem is false results: breath tests miss many true cases and flag some people who do not have it. (Source 3)

How can you test for it, and how reliable is that test?

Culture of small-bowel fluid or a glucose or lactulose breath test. Breath tests have modest accuracy (glucose better than lactulose), and culture is invasive and may underestimate bacteria. (Source 3)

References

1. American Journal of Gastroenterology (American College of Gastroenterology). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. 2020. PMID 32023228, DOI 10.14309/ajg.0000000000000501. Read the source
2. Frontiers in Microbiology. Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis. 2026. PMID 41883799, DOI 10.3389/fmicb.2026.1780567. Read the source
3. Journal of Neurogastroenterology and Motility. Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. 2020. PMID 31743632, DOI 10.5056/jnm19113. Read the source
4. Journal of Clinical Medicine. Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth. 2026. PMID 42355617, DOI 10.3390/jcm15124449. Read the source